Apyx Medical Inc (APYX)vsDexCom Inc (DXCM)
APYX
Apyx Medical Inc
$2.90
+0.35%
HEALTHCARE · Cap: $129.74M
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 8407% more annual revenue ($4.97B vs $58.41M). DXCM leads profitability with a 20.1% profit margin vs -14.8%. APYX appears more attractively valued with a PEG of 0.59. DXCM earns a higher WallStSmart Score of 74/100 (B).
APYX
Hold38
out of 100
Grade: F
DXCM
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.2%
Fair Value
$5.70
Current Price
$2.90
$2.80 discount
Intrinsic value data unavailable for DXCM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Revenue surging 22.1% year-over-year
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
Trading at 11.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 11.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : APYX
The strongest argument for APYX centers on PEG Ratio, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : APYX
The primary concerns for APYX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.72 is elevated, increasing financial risk.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
APYX profiles as a growth stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.42 — expect wider price swings.
APYX is growing revenue faster at 22.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 38/100), backed by strong 20.1% margins and 13.1% revenue growth. APYX offers better value entry with a 31.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apyx Medical Inc
HEALTHCARE · MEDICAL DEVICES · USA
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?